Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema

The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in ophthalmological medicine 2022-01, Vol.2022, p.3755249-4
Main Authors: Chakraborty, Somnath, Sheth, Jay Umed
Format: Article
Language:English
Subjects:
Case Report
Case reports
Diabetes
Diabetic retinopathy
Dropsy
Edema
Eyes & eyesight
Injections
Monoclonal antibodies
Ophthalmology
Pegaptanib
Permeability
Pharmacokinetics
Vascular endothelial growth factor
Visual impairment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863
cites cdi_FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863
container_end_page 4
container_issue
container_start_page 3755249
container_title Case reports in ophthalmological medicine
container_volume 2022
creator Chakraborty, Somnath
Sheth, Jay Umed
description The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.
doi_str_mv 10.1155/2022/3755249
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a6ae98fc208f49cca3d1abed26b0fb03</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A821452918</galeid><doaj_id>oai_doaj_org_article_a6ae98fc208f49cca3d1abed26b0fb03</doaj_id><sourcerecordid>A821452918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863</originalsourceid><addsrcrecordid>eNp9Ul1rFDEUHUSxpfbNZxnwUbfN90xehLquulDxRd-EcCdzs80yO6mZmRb99d7trqsLYgJJuOfcw8nlFMVzzi441_pSMCEuZaW1UPZRcSqYZTNTSfb48BbipDgfhjWjZZjgRj0tTqTmouK1PS2-zVM_ZuhgRDrLRQjoxzKkrkv3sV-Vyy16F8eMhL7NqZt8_DltoCFkTdSY-jL25bsIDY7Rl5_ATx3kctHiBp4VTwJ0A57v77Pi6_vFl_nH2fXnD8v51fXMq6oeZ1oyhRKtUpYj50aaBiRrKokgfMsDBpShMqLxSpJ_EKq1xmrGvRFa1EaeFcudbptg7W5z3ED-4RJE91BIeeUgk7sOHRhAWwcvWB2U9R5ky8l6K0zDQsMkab3Zad1OzQZbjw_jORI9Rvp441bpztU1N4YpEni5F8jp-4TD6NZpyj393wnya7mSVv9hrYBcxT4kEvObOHh3VQuutLC8JtbFP1i0abrRpx5DpPpRw-tdg89pGDKGg3HO3DYxbpsYt08M0V_8_dkD-Xc-iPBqR7iJfQv38f9yvwCopMc6</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2625914395</pqid></control><display><type>article</type><title>Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Wiley Open Access Journals</source><creator>Chakraborty, Somnath ; Sheth, Jay Umed</creator><contributor>Campa, Claudio ; Claudio Campa</contributor><creatorcontrib>Chakraborty, Somnath ; Sheth, Jay Umed ; Campa, Claudio ; Claudio Campa</creatorcontrib><description>The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.</description><identifier>ISSN: 2090-6722</identifier><identifier>EISSN: 2090-6730</identifier><identifier>DOI: 10.1155/2022/3755249</identifier><identifier>PMID: 35127189</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Case Report ; Case reports ; Diabetes ; Diabetic retinopathy ; Dropsy ; Edema ; Eyes &amp; eyesight ; Injections ; Monoclonal antibodies ; Ophthalmology ; Pegaptanib ; Permeability ; Pharmacokinetics ; Vascular endothelial growth factor ; Visual impairment</subject><ispartof>Case reports in ophthalmological medicine, 2022-01, Vol.2022, p.3755249-4</ispartof><rights>Copyright © 2022 Somnath Chakraborty and Jay Umed Sheth.</rights><rights>COPYRIGHT 2022 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2022 Somnath Chakraborty and Jay Umed Sheth. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Somnath Chakraborty and Jay Umed Sheth. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863</citedby><cites>FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863</cites><orcidid>0000-0001-7913-9328 ; 0000-0002-3590-7759</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2625914395/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2625914395?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35127189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Campa, Claudio</contributor><contributor>Claudio Campa</contributor><creatorcontrib>Chakraborty, Somnath</creatorcontrib><creatorcontrib>Sheth, Jay Umed</creatorcontrib><title>Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema</title><title>Case reports in ophthalmological medicine</title><addtitle>Case Rep Ophthalmol Med</addtitle><description>The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.</description><subject>Case Report</subject><subject>Case reports</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Dropsy</subject><subject>Edema</subject><subject>Eyes &amp; eyesight</subject><subject>Injections</subject><subject>Monoclonal antibodies</subject><subject>Ophthalmology</subject><subject>Pegaptanib</subject><subject>Permeability</subject><subject>Pharmacokinetics</subject><subject>Vascular endothelial growth factor</subject><subject>Visual impairment</subject><issn>2090-6722</issn><issn>2090-6730</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9Ul1rFDEUHUSxpfbNZxnwUbfN90xehLquulDxRd-EcCdzs80yO6mZmRb99d7trqsLYgJJuOfcw8nlFMVzzi441_pSMCEuZaW1UPZRcSqYZTNTSfb48BbipDgfhjWjZZjgRj0tTqTmouK1PS2-zVM_ZuhgRDrLRQjoxzKkrkv3sV-Vyy16F8eMhL7NqZt8_DltoCFkTdSY-jL25bsIDY7Rl5_ATx3kctHiBp4VTwJ0A57v77Pi6_vFl_nH2fXnD8v51fXMq6oeZ1oyhRKtUpYj50aaBiRrKokgfMsDBpShMqLxSpJ_EKq1xmrGvRFa1EaeFcudbptg7W5z3ED-4RJE91BIeeUgk7sOHRhAWwcvWB2U9R5ky8l6K0zDQsMkab3Zad1OzQZbjw_jORI9Rvp441bpztU1N4YpEni5F8jp-4TD6NZpyj393wnya7mSVv9hrYBcxT4kEvObOHh3VQuutLC8JtbFP1i0abrRpx5DpPpRw-tdg89pGDKGg3HO3DYxbpsYt08M0V_8_dkD-Xc-iPBqR7iJfQv38f9yvwCopMc6</recordid><startdate>20220128</startdate><enddate>20220128</enddate><creator>Chakraborty, Somnath</creator><creator>Sheth, Jay Umed</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7913-9328</orcidid><orcidid>https://orcid.org/0000-0002-3590-7759</orcidid></search><sort><creationdate>20220128</creationdate><title>Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema</title><author>Chakraborty, Somnath ; Sheth, Jay Umed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>Case reports</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Dropsy</topic><topic>Edema</topic><topic>Eyes &amp; eyesight</topic><topic>Injections</topic><topic>Monoclonal antibodies</topic><topic>Ophthalmology</topic><topic>Pegaptanib</topic><topic>Permeability</topic><topic>Pharmacokinetics</topic><topic>Vascular endothelial growth factor</topic><topic>Visual impairment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chakraborty, Somnath</creatorcontrib><creatorcontrib>Sheth, Jay Umed</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ: Directory of Open Access Journals</collection><jtitle>Case reports in ophthalmological medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chakraborty, Somnath</au><au>Sheth, Jay Umed</au><au>Campa, Claudio</au><au>Claudio Campa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema</atitle><jtitle>Case reports in ophthalmological medicine</jtitle><addtitle>Case Rep Ophthalmol Med</addtitle><date>2022-01-28</date><risdate>2022</risdate><volume>2022</volume><spage>3755249</spage><epage>4</epage><pages>3755249-4</pages><issn>2090-6722</issn><eissn>2090-6730</eissn><abstract>The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>35127189</pmid><doi>10.1155/2022/3755249</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-7913-9328</orcidid><orcidid>https://orcid.org/0000-0002-3590-7759</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-6722
ispartof Case reports in ophthalmological medicine, 2022-01, Vol.2022, p.3755249-4
issn 2090-6722
2090-6730
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a6ae98fc208f49cca3d1abed26b0fb03
source Open Access: PubMed Central; Publicly Available Content Database; Wiley Open Access Journals
subjects Case Report
Case reports
Diabetes
Diabetic retinopathy
Dropsy
Edema
Eyes & eyesight
Injections
Monoclonal antibodies
Ophthalmology
Pegaptanib
Permeability
Pharmacokinetics
Vascular endothelial growth factor
Visual impairment
title Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contralateral%20Effect%20following%20Intravitreal%20Brolucizumab%20Injection%20in%20Diabetic%20Macular%20Edema&rft.jtitle=Case%20reports%20in%20ophthalmological%20medicine&rft.au=Chakraborty,%20Somnath&rft.date=2022-01-28&rft.volume=2022&rft.spage=3755249&rft.epage=4&rft.pages=3755249-4&rft.issn=2090-6722&rft.eissn=2090-6730&rft_id=info:doi/10.1155/2022/3755249&rft_dat=%3Cgale_doaj_%3EA821452918%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-5304e3e94491e11636ba30b73ea2cd1fefe3f762bc43164a24d969501c6252863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2625914395&rft_id=info:pmid/35127189&rft_galeid=A821452918&rfr_iscdi=true